ClinicalTrials.gg
TerminatedNCT04557384Updated Feb 27, 2023Results posted

A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer

A Phase 1 interventional study of Ramucirumab in Advanced Solid Tumor, sponsored by Eli Lilly and Company. Terminated at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-27.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Why this study was terminated
Study terminated due to inadequate PK profile associated with the subcutaneous formulation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study in participants with advanced cancer is to learn more about the safety of ramucirumab when given by injection under the skin (subcutaneous injection). The study will also measure how much ramucirumab gets into the bloodstream and how long it takes the body to get rid of it.

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Safety
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have evaluable disease per version 1.1 (RECIST 1.1).
  • In the judgment of the investigator, be an appropriate candidate for experimental therapy and:

    • For Cohort A only: Have exhausted all anticancer treatments with proven clinical benefit OR
    • For Cohorts B and C only: Must have one of the three conditions below:

      • Have exhausted all anti-cancer treatments with proven clinical benefit, OR
      • Have hepatocellular carcinoma or gastric cancer who have received prior treatment, and where IV ramucirumab monotherapy is clinically acceptable treatment after progression OR
      • Have a diagnosis for which IV ramucirumab in combination with additional anticancer therapy is clinically acceptable treatment
      • Additionally, it must be clinically acceptable to delay initiation of the combination partner for 3 weeks from the initiation of ramucirumab dosing.
  • performance status score of 0 or 1.
  • Have discontinued all previous treatments for cancer with adequate and recovered from the acute effects of therapy.
  • Have adequate hematologic, hepatic, and renal functions and electrolytes.
  • Males and females of must agree to use highly effective methods during study treatment and for at least 84 days/12 weeks following the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Have uncontrolled hypertension defined as systolic blood pressure (BP) >150 mmHg or diastolic BP >90 mmHg despite standard medical management.
  • Have significant bleeding disorders or experienced Grade 3/4 gastrointestinal (GI) bleeding within 3 months prior to enrollment.
  • Have hepatic impairment (such as severe liver cirrhosis B [or worse], cirrhosis with a history of hepatic encephalopathy, ascites requiring ongoing treatment with diuretics and/or paracentesis, or history of hepatorenal syndrome).
  • Have experienced any arterial thromboembolic events (ATEs), including but not limited to myocardial infarction, , cerebrovascular accident, or unstable angina, ≤6 months prior to randomization.
  • The participant has clinically relevant congestive heart failure (CHF; [NYHA] Grade ≥2) or symptomatic or poorly controlled cardiac arrhythmia.
  • Have symptomatic central nervous system (CNS) . Screening is not required.
  • Have history of GI perforation and/or fistula within 6 months prior to enrollment.
  • Have an active uncontrolled systemic bacterial, viral, or fungal infection or serious ongoing uncontrolled intercurrent illness.
  • Have a serious or non-healing wound, ulcer, or bone fracture within 4 weeks prior to enrollment.
  • Have received IV ramucirumab in the past.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Ramucirumab

    Participants received starting dose of 700 milligram (mg) ramucirumab loading dose (LD) subcutaneously (SC) followed, a week later, by 350 mg ramucirumab maintenance dose (MD) administered SC once a week.

    Drug: Ramucirumab

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Ramucirumab

    PK: AUC of Ramucirumab over the dosing interval was evaluated. Cycle = 21 days.

    Time frame: Cycle (C) 1 Day (D) 1:Predose; C1D2:24 hours (h) postdose;C1D4:48-96 h postdose;C1D8:predose;C1D15:predose;C1D18:48-96 h postdose;C2D1:predose;C2D8:predose;C2D11:48-96h postdose;C3D1:predose

  2. PK: Maximum Concentration (Cmax) of Ramucirumab

    PK: Cmax of Ramucirumab was evaluated.

    Time frame: C1D1:Predose; C1D2:24 hours (h) postdose;C1D4:48-96 h postdose;C1D8:predose;C1D15:predose;C1D18:48-96 h postdose;C2D1:predose;C2D8:predose;C2D11:48-96h postdose;C3D1:predose

  3. PK: Serum Trough Concentration (Ctrough) of Ramucirumab

    Ctrough of Ramucirumab was evaluated.

    Time frame: C1D8: predose; C1D15: predose; C2D1: predose; C2D8: predose; C3D1: predose

Secondary outcomes

  1. Percentage of Participants With Anti-Ramucirumab Antibodies

    Percentage of participants with positive treatment emergent anti-drug antibodies was summarized by treatment group. A treatment-emergent ADA (TEADA) was defined as: having a negative ADA at baseline and an ADA titer greater than or equal to 1:20 (that is (i.e.), greater than 2-fold from the minimal required dilution of 1:10) any time post baseline (i.e., treatment-induced); or a 4-fold or greater change in ADA titer from baseline for participants that had a detectable ADA titer at baseline (i.e., treatment boosted).

    Time frame: C1D1: predose; C1D15: predose; C2D8: predose; C4D1: predose

  2. Number of Participants With Injection Site Reactions (ISRs)

    The number of participants with at least one treatment-emergent injection site reaction is presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Cycle 1, Cycle 2, Cycle 3: D1, D8, D15, D22: 5-15 min, 60 min post injection; C1D2: 24 hours (h) post injection; C1D4 (± 1 day)

07

Results

Posted Feb 27, 2023
Limitations and caveats
Study was terminated due to low likelihood of achieving a relevant therapeutic exposure.

Participant flow

Participant flow — Overall Study
MilestoneRamucirumab
Started3
Received at least 1 dose of study drug3
Completed1
Not completed2
Withdrew: Study terminated by sponsor1
Withdrew: Death1

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Ramucirumab

PK: AUC of Ramucirumab over the dosing interval was evaluated. Cycle = 21 days.

Time frame:
Cycle (C) 1 Day (D) 1:Predose; C1D2:24 hours (h) postdose;C1D4:48-96 h postdose;C1D8:predose;C1D15:predose;C1D18:48-96 h postdose;C2D1:predose;C2D8:predose;C2D11:48-96h postdose;C3D1:predose
Reported as:
Geometric mean · nanograms*hours/milliliter (ng*hr/mL)
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Ramucirumab
nanograms*hours/milliliter (ng*hr/mL)Ramucirumab
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of RamucirumabNA ± NA
PrimaryPK: Maximum Concentration (Cmax) of Ramucirumab

PK: Cmax of Ramucirumab was evaluated.

Time frame:
C1D1:Predose; C1D2:24 hours (h) postdose;C1D4:48-96 h postdose;C1D8:predose;C1D15:predose;C1D18:48-96 h postdose;C2D1:predose;C2D8:predose;C2D11:48-96h postdose;C3D1:predose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Maximum Concentration (Cmax) of Ramucirumab
nanograms per milliliter (ng/mL)Ramucirumab
PK: Maximum Concentration (Cmax) of RamucirumabNA ± NA
PrimaryPK: Serum Trough Concentration (Ctrough) of Ramucirumab

Ctrough of Ramucirumab was evaluated.

Time frame:
C1D8: predose; C1D15: predose; C2D1: predose; C2D8: predose; C3D1: predose
Reported as:
Geometric mean · microgram per milliliter (µg/mL)
PK: Serum Trough Concentration (Ctrough) of Ramucirumab
microgram per milliliter (µg/mL)Ramucirumab
C1D812.6 ± 79
C1D1520.9 ± 41.6
C2D1NA ± NA
C2D8NA ± NA
C3D1NA ± NA
SecondaryPercentage of Participants With Anti-Ramucirumab Antibodies

Percentage of participants with positive treatment emergent anti-drug antibodies was summarized by treatment group. A treatment-emergent ADA (TEADA) was defined as: having a negative ADA at baseline and an ADA titer greater than or equal to 1:20 (that is (i.e.), greater than 2-fold from the minimal required dilution of 1:10) any time post baseline (i.e., treatment-induced); or a 4-fold or greater change in ADA titer from baseline for participants that had a detectable ADA titer at baseline (i.e., treatment boosted).

Time frame:
C1D1: predose; C1D15: predose; C2D8: predose; C4D1: predose

No measurements were reported for this outcome.

SecondaryNumber of Participants With Injection Site Reactions (ISRs)

The number of participants with at least one treatment-emergent injection site reaction is presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Cycle 1, Cycle 2, Cycle 3: D1, D8, D15, D22: 5-15 min, 60 min post injection; C1D2: 24 hours (h) post injection; C1D4 (± 1 day)
Reported as:
Number · participants
Number of Participants With Injection Site Reactions (ISRs)
participantsRamucirumab
Number of Participants With Injection Site Reactions (ISRs)1

Adverse events

Collected over Up To 40 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ramucirumab1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventRamucirumab
Pancreatitis acuteGastrointestinal disorders1/3
AstheniaGeneral disorders1/3
PneumoniaInfections and infestations1/3
Most frequent other events
Showing 10 of 23
Most frequent other events
EventRamucirumab
Muscular weaknessMusculoskeletal and connective tissue disorders2/3
Abdominal painGastrointestinal disorders1/3
ConstipationGastrointestinal disorders1/3
DyspepsiaGastrointestinal disorders1/3
NauseaGastrointestinal disorders1/3
PancreatitisGastrointestinal disorders1/3
Pancreatitis acuteGastrointestinal disorders1/3
VomitingGastrointestinal disorders1/3
FatigueGeneral disorders1/3
Generalised oedemaGeneral disorders1/3

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Ramucirumab
Mean66.67 ± 5.508
Sex: Female, Male
Sex: Female, Male(Participants)Ramucirumab
Female0
Male3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ramucirumab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White2
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Ramucirumab
United States3
08

Study locations

5 sites
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • Oncology Hematology West
    Omaha, Nebraska 68130, United States
  • Levine Cancer Institute- Carolinas Medical Center
    Charlotte, North Carolina 28204, United States
  • Tennessee Oncology PLLC
    Nashville, Tennessee 37203, United States
  • Kindai University Hospital
    Osaka Sayama-shi, Osaka 589 8511, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in May 2021, 3 months.

Results were first posted in Feb 2023, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2020
First posted
Sep 21, 2020
StartActual
Feb 23, 2021
Primary completionActual
May 25, 2021
CompletionActual
May 25, 2021
Results first posted
Feb 27, 2023
Last update
Feb 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04557384
Responsible party
Sponsor
First posted
Sep 21, 2020
Start date
Feb 23, 2021
Primary completion
May 25, 2021
Completion
May 25, 2021
Results posted
Feb 27, 2023
Last update
Feb 27, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion